China rejects patent on hepatitis C drug sofosbuvir.


The Chinese patent office has rejected a patent application for the blockbuster hepatitis C treatment sofosbuvir, increasing the possibility of a generic version of the drug to become available in China. The decision comes after a challenge by the Initiative for Medicines, Access and Knowledge (I-MAK), a US based group that campaigns for better access to… (More)
DOI: 10.1136/bmj.h3429


Blog articles referencing this paper